{"preliminary_commentary":{"by_channel":{"x_thread":3},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":[["abiraterone"]],"indication":"castration-resistant prostate cancer","name":"NCT02025010","nct_id":"NCT02025010","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct02025010. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Participants will be treated with four 250 mg tablets (1,000 mg) of abiraterone acetate (AA) orally on 28-day cycles. For participants who experience persistent or severe mineralocorticoid excess or have PSA progression, prednisone 5 mg by mouth twice daily will be added.\n\nPatients will be treated until radiographic disease progression and unacceptable AE or taken off study for other reason.","label":"abiraterone acetate","type":"EXPERIMENTAL"}],"collaborators":["Janssen Research & Development, LLC"],"completion_date":{"date":"2025-04-07","type":"ACTUAL"},"conditions":["Castration-resistant Prostate Cancer"],"enrollment":{"count":60,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"abiraterone acetate","otherNames":["JNJ21208"],"type":"DRUG"}],"last_update":"2025-04-15","lead_sponsor":"Dana-Farber Cancer Institute","official_title":"Phase II Clinical Trial of Abiraterone Acetate Without Exogenous Glucocorticoids in Men With Castration-resistant Prostate Cancer With Correlative Assessment of Hormone Intermediates.","overall_status":"COMPLETED","phases":["PHASE2"],"primary_completion_date":{"date":"2021-12","type":"ACTUAL"},"primary_outcomes":[{"measure":"Number of Participants With Toxicities That Required the Addition of Prednisone to Manage Symptoms of Persistent or Severe Mineralocorticoid Excess","timeFrame":"Patients were on abiraterone acetate up to 57 months and toxicities of mineralocorticoid excess were monitored each cycle (1cycle = 28 days)."}],"references":[{"citation":"Sperger JM, Emamekhoo H, McKay RR, Stahlfeld CN, Singh A, Chen XE, Kwak L, Gilsdorf CS, Wolfe SK, Wei XX, Silver R, Zhang Z, Morris MJ, Bubley G, Feng FY, Scher HI, Rathkopf D, Dehm SM, Choueiri TK, Halabi S, Armstrong AJ, Wyatt AW, Taplin ME, Zhao SG, Lang JM. Prospective Evaluation of Clinical Outcomes Using a Multiplex Liquid Biopsy Targeting Diverse Resistance Mechanisms in Metastatic Prostate Cancer. J Clin Oncol. 2021 Sep 10;39(26):2926-2937. doi: 10.1200/JCO.21.00169. Epub 2021 Jul 1.","pmid":"34197212","type":"DERIVED"}],"start_date":{"date":"2014-01-27","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Study of Abiraterone Acetate Without Exogenous Glucocorticoids in Men With Castration-resistant Prostate Cancer","url":"https://clinicaltrials.gov/study/NCT02025010"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.1","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct02025010"}